A5103136138- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Head and Neck Cancer Studies
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiopharmaceutical Chemistry and Applications
- COVID-19 and healthcare impacts
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Salivary Gland Tumors Diagnosis and Treatment
- Spanish Philosophy and Literature
- Biosimilars and Bioanalytical Methods
- Angiogenesis and VEGF in Cancer
- vaccines and immunoinformatics approaches
- Genetic factors in colorectal cancer
- Polyomavirus and related diseases
Hospital General Universitario De Valencia
2014-2024
Universidad Autónoma de Madrid
2006-2021
Ajuntament de L’Hospitalet
2018
Santa Lucía University General Hospital
2015
Instituto Oncológico Dr. Rosell
2015
Hospital General Universitario Gregorio Marañón
2015
Research Institute Hospital 12 de Octubre
2015
GEICAM – Spanish Breast Cancer Group
2012
Universidad Peruana Cayetano Heredia
2006
Hospital Nacional Cayetano Heredia
2006
Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP-004 study to evaluate combination multikinase inhibitor lenvatinib and PD-1 pembrolizumab in this population (ClinicalTrials.gov identifier: NCT03776136).Eligible patients with unresectable stage III-IV confirmed progressive disease (PD) within 12 weeks last dose a PD-1/L1 given alone other therapies, including cytotoxic...
Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess utilization survival outcomes R/M HNSCC in the real-world setting. A multi-site retrospective chart review was conducted Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), Latin/North America (Brazil Canada) identify who initiated first-line systemic therapy between...
6009 Background: Induction chemotherapy (IC) with TPF isa standard regimen for patients (pts) locally advanced head and neck squamous cell carcinoma (N Engl J Med. 2007;357:1705–1715). However, CRT alone is treatment unresectable LAHNC. We designed a trial to compare two different regimens of IC followed by versus in pts Methods: Pts unresectable, measurable LAHNC, adequate organ function, ECOG 0–1 were enrolled stratified according primary tumor site. (3 cycles): PF (cisplatin 100 mg/m 2...
Abstract Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients advanced melanoma harboring activating mutations. Previous preclinical studies suggested that an intermittent dosing of these drugs could delay the emergence resistance. Contrary to expectations, first published phase 2 randomized study comparing continuous versus schedule dabrafenib trametinib a detrimental effect “on−off” schedule. Here we report confirmatory data from...
Epidermal growth factor receptor gene (EGFR) alteration is a common feature in most of glioblastoma multiforme (GBM). Robust response anti-EGFR treatments has been mostly associated with the EGFR deletion mutant variant III (EGFRvIII) and expression PTEN. We have performed prospective trial order to confirm efficacy erlotinib treatment patients relapsed GBM who expressed EGFRvIII All included were required be PTEN (+++), (+++) positives by immunohistochemistry. This new phase II enrolled 40...
Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by questionnaire on the demographics, outcomes, toxicity of ipilimumab administered through an Expanded Access Program (EAP). Ipilimumab 3 mg/kg was intravenously every weeks for four cycles adults with Efficacy outcomes included complete response, partial...
Abstract Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society Medical Oncology (SEOM) and Multidisciplinary Group (GEM) has designed these guidelines to homogenize the management patients. The diagnosis must be histological determination BRAF status performed with stage ≥ III. Stage I–III resectable melanomas will treated surgically. In III melanoma, adjuvant treatment immunotherapy or targeted therapy is also recommended. Patients...
9504 Background: Initial results of the open-label, single-arm, phase 2 LEAP-004 study (NCT03776136) showed that len and pembro in combination had promising efficacy manageable safety pts with unresectable stage III-IV melanoma confirmed PD on a PD-(L)1 inhibitor given alone or combination. ORR was 21.4% 6.3-mo median DOR; 31.0% patients prior anti–PD-1 + anti–CTLA-4. We present updated data from additional subgroup analyses. Methods: Eligible per iRECIST within 12 wk last dose anti–CTLA-4...
Background: Covid-19 pandemic by the new coronavirus SARS-Cov-2 has produced devastating effects on health care system, affecting also cancer patient care. Data about COVID-19 infection in patients are scarce, and they point out a higher risk of complications due to viral this population. Moreover, treatments could increase complications, specially those based use immunotherapy with checkpoints antibodies. There no clinical data safety immune check antibodies when become infected SARS-CoV-2....
Purpose: HIV-associated Kaposi's sarcoma (KS) may not resolve despite highly active antiretroviral therapy (HAART). Moreover, the therapeutic goal has shifted from palliative care to long-term durable complete remission. The objective of study was assess impact liposomal doxorubicin in treatment KS HAART era. Method: In this prospective, noncomparative, multicenter study, patients with more than 10 cutaneous lesions or visceral disease were treated 20 mg/m2 (Caelyx®) every 3 weeks addition...